Previous article Next article

ALERTS: UNILATERAL PRACTICES - FRANCE - PHARMACEUTICAL SECTOR - HEALTHCARE - ABUSE OF DOMINANT POSITION - COLLECTIVE DOMINANT POSITION - FINES

Collective dominant position: The French Competition Authority sanctions pharmaceutical companies for abusing their collective dominant position in the French market for the treatment of age-related macular degeneration with a fine of 444 million euros (Novartis, Roche and Genentech)

New

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. By Decision No. 20-D-11 of 9 September 2020The French Competition Authority has imposed a fine of 444 million euros on the Novartis group and the Roche/Genentech group (385 million for Novartis alone) for abusing their collective dominant position on the French market for the treatment of age-related macular degeneration (AMD), by implementing two distinct practices, albeit close to each other and in any case serving the same purpose, for the attention of, on the one hand, health professionals, health sector authorities, patients and the general public and, on the other hand, politicians and health authorities. This case follows a report sent by the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • L’actu-concurrence (Paris)

Quotation

Alain Ronzano, Collective dominant position: The French Competition Authority sanctions pharmaceutical companies for abusing their collective dominant position in the French market for the treatment of age-related macular degeneration with a fine of 444 million euros (Novartis, Roche and Genentech), 9 September 2020, Concurrences N° 4-2020, Art. N° 96689, www.concurrences.com

Visites 147

All reviews